What is ProciseDx?
Founded in 2018 and headquartered in San Diego, California, ProciseDx operates at the intersection of biotechnology and clinical efficiency. The company specializes in the development and commercialization of a comprehensive portfolio of point-of-care diagnostic tests. By targeting physician offices, retail clinics, and urgent care facilities, ProciseDx addresses the critical need for rapid, actionable diagnostic data at the point of patient interaction. This market positioning allows the firm to bypass the latency associated with centralized laboratory testing, thereby enhancing patient outcomes and operational throughput for healthcare providers.
How much funding has ProciseDx raised?
ProciseDx has raised a total of $10.5M across 1 funding round:
Series A
$10.5M
Series A (2020): $10.5M with participation from Biosynex and Nestle Health Science
Key Investors in ProciseDx
Biosynex
A French leader in the design, manufacture, and distribution of rapid diagnostic tests for professional and public use.
Nestle Health Science
A global health and nutrition company focused on advancing the therapeutic role of nutrition to change the course of health management.
What's next for ProciseDx?
Following this major strategic investment, ProciseDx is expected to scale its manufacturing capabilities and expand its commercial footprint across the United States. The capital will likely be deployed to finalize regulatory pathways for its pipeline of diagnostic assays and to strengthen its distribution network within the urgent care and retail clinic segments. As the company transitions from its initial development phase into a more mature commercial entity, the focus will shift toward achieving widespread clinical adoption and establishing long-term partnerships with major healthcare delivery systems. The backing from established industry players suggests a robust roadmap for product integration and market penetration in the coming fiscal periods.
See full ProciseDx company page
